Holen Sie sich die Stockscreener-App
53.57
3.60%
1.86
Moderna Inc Aktie (MRNA) Neueste Nachrichten
Rothschild & Co Redburn Adjusts Price Target on Moderna to $40 From $36, Maintains Neutral Rating - marketscreener.com
Uncertainty Looms Over Pharma’s Legal Strategy as States Challenge New Vaccine Schedule - BioSpace
Moderna (MRNA) Gains EMA Recommendation for Combo Vaccine - GuruFocus
Why Is Moderna Stock Moving Today? Europe Clears Moderna’s Dual Vaccine - Tokenist
EU regulator backs approval for Moderna’s combined COVID, flu shot - WTVB
EU regulator backs approval for Moderna's combined COVID and flu vaccine - marketscreener.com
Moderna Gets EU Approval for mRNA Combination Covid-Flu Shot - Bloomberg.com
Moderna’s flu-COVID combo vaccine gets EU regulatory backing By Investing.com - Investing.com India
Moderna Says It Received Positive EU Panel Opinion for Flu-COVID Combination Vaccine - marketscreener.com
Moderna (MRNA) Gains Positive Opinion for Combo Vaccine in EU - GuruFocus
Moderna (MRNA) Nears EU Approval for Combined Flu and COVID-19 V - GuruFocus
Moderna’s Covid-Flu Vaccine Recommended for Approval in EU - WSJ
World’s first flu-COVID combo shot wins key EU backing for over-50s - Stock Titan
Moderna’s combination flu, COVID shot wins over European drug regulators - Yahoo Finance
Moderna Wins European Medicines Agency's Positive Opinion for Combined COVID-19, Influenza Vaccine - marketscreener.com
Ema recommends granting marketing authorisation in EU for mCombriax - marketscreener.com
Moderna (MRNA) Is Up 10.2% After FDA Accepts Full Review Of Its mRNA Flu Vaccine - simplywall.st
Moderna (MRNA) Stock Review: Performance & Valuation Concerns in 2026News and Statistics - IndexBox
Moderna president Hoge sells $7.8m in MRNA stock - Investing.com South Africa
Moderna president Hoge sells $7.8m in MRNA stock By Investing.com - Investing.com Canada
Stephen Hoge Sells 160,009 Shares of Moderna (NASDAQ:MRNA) Stock - MarketBeat
Moderna Royalty Opinion Loss Raises Covid-Shot Trial Stakes (1) - Bloomberg Law News
Moderna's Damages Expert Limited In March Patent Trial - Law360
Moderna's Ups and Downs: Here's What You Need to Know Before Investing. - Nasdaq
Moderna's Ups and Downs: Here's What You Need to Know Before Investing. - The Motley Fool
3 Reasons to Avoid MRNA and 1 Stock to Buy Instead - Finviz
A Fresh Look At Moderna (MRNA) Valuation After A Sharp Share Price Rebound - Yahoo Finance Singapore
MRNA Stock Surges 26% With A 7-day Winning Spree On FDA Flu Vaccine Review - Trefis
How To Read FDA's Flip-Flop On Moderna Flu Vaccine - Law360
What the Options Market Tells Us About ModernaModerna (NASDAQ:MRNA) - Benzinga
Moderna says FDA will consider its new flu shot after resolving public dispute - Devils Lake Journal
Moderna Stock: How Far Can The Flu Shot Fly? - Forbes
Will the FDA yank mRNA vaccines? - PharmaVoice
Moderna Shares Surge on Stronger-Than-Expected Revenue and Strategic Pivot - AD HOC NEWS
MRNA Stock Surges 25% With A 6-day Winning Spree On FDA Flu Shot Review - Trefis
Gilead’s Arcellx buy. Plus: ctDNA as surrogate endpoint — a BioCentury podcast - biocentury.com
US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost - marketscreener.com
Moderna, Inc. (MRNA) Stock Analysis: Navigating a -15.68% Potential Downside Amid Revenue Challenges - DirectorsTalk Interviews
Moderna Faces New Challenges and Opportunities Ahead - Intellectia AI
Moderna’s Stock Surges Amid New Agreements and Regulatory Approvals - StocksToTrade
Piper Sandler raises Moderna stock price target on vaccine pipeline By Investing.com - Investing.com India
Piper Sandler raises Moderna stock price target on vaccine pipeline - Investing.com
Here's Why I Wouldn't Touch Moderna With a 10‑Foot Pole Until Its Next Growth Engine Is Clear - Yahoo Finance
Piper Sandler Revises Price Target for MRNA, Maintains 'Overweig - GuruFocus
Scientists identify new spinosaurid, Moderna flu shot back on track, universal inhaled vaccine shows promise - Scientific American
Aberdeen Group plc Reduces Stock Holdings in Moderna, Inc. $MRNA - MarketBeat
Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission - ACCESS Newswire
Moderna (MRNA) Leads Healthcare Gains with 24.33% Surge - GuruFocus
500,000 Shares in Moderna, Inc. $MRNA Bought by Telemark Asset Management LLC - MarketBeat
Vanguard Group Inc. Has $1.06 Billion Stock Position in Moderna, Inc. $MRNA - MarketBeat
Moderna Faces Default Risk as Ares Capital–Led Lenders Gain Power to Accelerate Debt and Seize Collateral - TipRanks
Times Opinion: Letting disease win — FDA’s dangerous refusal of Moderna’s new mRNA flu vaccine - Chattanooga Times Free Press
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Cuts Stake in Moderna, Inc. $MRNA - MarketBeat
Decoding Moderna Inc (MRNA): A Strategic SWOT Insight - GuruFocus
BioNTech Says Moderna's New COVID Vax Infringes Its IP - Law360
Court Narrows Moderna Defenses in Arbutus Patent Dispute - TipRanks
MRNA Stock Quote Price and Forecast - CNN
Moderna (MRNA) Shows Mixed Options Sentiment Amid Modest Price D - GuruFocus
Moderna, Inc. SEC 10-K Report - TradingView
Arbutus Biopharma wins partial summary judgment on Moderna defenses; enablement dispute to go to jury - TradingView
MRNAModerna Inc Stock Price and Quote - Finviz
BioNTech Files Suit Against Moderna for Patent Infringement - Pharmaceutical Executive
Netflix, Klarna, Shopify, Palo Alto, Moderna: What brokers said this week - Proactive financial news
Moderna and Merck Advance mRNA Cancer Vaccine Trial in First-Line Lung Cancer: What Investors Should Watch - TipRanks
Moderna Faces Lawsuit From BioNTech Over Next-Generation COVID-19 Shot - Benzinga
Moderna (MRNA) Faces Legal Challenge Over COVID-19 Vaccine Paten - GuruFocus
FDA reverses course on Moderna mRNA flu vaccine, review initiated - Fox Business
GSK Can Tweak COVID Vaccine UPC Claim Against Moderna - Law360
RFK Jr.'s public health shakeups turning vaccine makers away - upi.com
BioNTech sues Moderna for patent infringement over COVID shots - Yahoo Finance
BioNTech Sues Moderna Over COVID-19 Vaccine Technology Patent - marketscreener.com
Moderna (MRNA) Faces Patent Lawsuit Over COVID-19 Vaccine - GuruFocus
GSA Capital Partners LLP Boosts Stock Position in Moderna, Inc. $MRNA - MarketBeat
1.58%
0.45%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):